nach oben

The European Journal of Health Economics

Erschienen in:

02.04.2016 | Original Paper

Social/economic costs and health-related quality of life in patients with scleroderma in Europe

verfasst von: Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Panos Kanavos, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, Márta Péntek, Claudia Delgado, Johann Mathias von der Schulenburg, Ulf Persson, Karine Chevreul, Giovanni Fattore, The BURQOL-RD Research Network

Erschienen in: The European Journal of Health Economics | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to determine the economic burden from a societal perspective and the health-related quality of life (HRQOL) of patients with systemic sclerosis (SSc; scleroderma) in Europe.

Methods

We conducted a cross-sectional study of patients with SSc (involving both localised and systemic sclerosis) from Germany, Italy, Spain, France, the UK, Hungary and Sweden. Data on demographic characteristics, healthcare resource utilisation, informal care, labour productivity losses and HRQOL were collected from the questionnaires completed by patients or their caregivers. HRQOL was measured with the EuroQol 5-domain (EQ-5D) questionnaire.

Results

A total of 589 patients completed the questionnaire. The rate of patients with localised scleroderma, limited cutan and diffuse cutan SSc were 28, 68 and 4 %, respectively. Average annual costs varied from country to country and ranged from € 4607 to € 30,797 (reference year: 2012). Estimated direct healthcare costs ranged from € 1413 to € 17,300; direct non-healthcare costs ranged from € 1875 to € 4684 and labour productivity losses ranged from € 1701 to € 14,444. The mean EQ-5D index score for adult SSc patients varied from 0.49 to 0.75 and the mean EQ-5D visual analogue scale score was between 58.72 and 65.86.

Conclusion

The main strengths of this study lie in our bottom-up approach to costing and our evaluation of SSs patients from a broad societal perspective. This type of analysis is very unusual in the international literature on rare diseases in comparison with other illnesses. We concluded that SSc patients incur considerable societal costs and experience substantial deterioration in HRQOL.

Nur mit Berechtigung zugänglich

Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E., Sibilia, J.: Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 37, 223–235 (2008)CrossRefPubMed

Czirjak, L., Kiss, C.G., Lovei, C., Suto, G., Varju, C., Fuzesi, Z.: Survey of Raynaud’s phenomenon and systemic sclerosis based on a representative study of 10,000 South-Transdanubian Hungarian inhabitants. Clin. Exp. Rheumatol. 23, 801–808 (2005)PubMed

Villaverde-Hueso, A., Posada-De-la-Paz, M., Martin-Arribas, M.C., Sanchez-Valle, E., Ramirez-Gonzalez, A., Biairdi, P.: Prevalence of scleroderma in Spain: an approach for estimating rare disease prevalence using a disease model. Pharmacoepidemiol. Drug Saf. 17, 1100–1107 (2008)CrossRefPubMed

Silman, A., Jannini, S., Symmons, D., Bacon, P.: An epidemiological study of scleroderma in the West Midlands. Br. J. Rheumatol. 27, 286–290 (1988)CrossRefPubMed

Arias-Nunez, M.C., Llorca, J., Vazquez-Rodriguez, T.R., Gomez-Acebo, I., Miranda-Filloy, J.A., Martin, J.: Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Med. (Baltimore). 87, 272–280 (2008)CrossRef

Haustein, U.F., Ziegler, V., Zschunke, E., et al.: Progressive systemic sclerosis with silicosis in the German Democratic Republic. In: Black, C.M., Myers, A.R. (eds.) Systemic sclerosis (scleroderma), pp. 138–142. Gower, New York (1985)

Monaco, A.L., Bruschi, M., Corte, R.L., et al.: Epidemiology of systemic sclerosis in a district of northern Italy. Clin. Exp. Rheumatol. 29(Suppl. 65), S10–S14 (2011)PubMed

Allcock, R.J., Forrest, I., Corris, P.A., Crook, P.R., Griffiths, I.D.: A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 43, 596–602 (2004)CrossRefPubMed

Andréasson, K., Saxne, T., Bergknut, C., Hesselstrand, R., Englund, M.: Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann. Rheum. Dis. 73(10), 1788–1792 (2014)CrossRefPubMed

10.

European Medicines Agency. Public summary of opinion on orphan designation. Committee for Orphan Medicinal Products. EMA/COMP/270/2003 Rev.2. 25 April 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005900.pdf (2014). Accessed 3 November 2015

11.

Hunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., et al.: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47, 1185–1192 (2008)CrossRefPubMedPubMedCentral

12.

Chung, L., Domsic, R.T., Lingala, B., Alkassab, F., Bolster, M., Csuka, M.E., et al.: Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res. (Hoboken) 66(3), 489–495 (2014)CrossRef

13.

Schouffoer, A., Zirkzee, E., Henquet, S., Caljouw, M., Steup-Beekman, G., van Laar, J.: Vliet Vlieland, T.: Needs and preferences regarding health care delivery as perceived by patients with systemic sclerosis. Clin. Rheumatol. 30, 815–824 (2011)CrossRefPubMedPubMedCentral

14.

López-Bastida, J., Linertová, R., Oliva-Moreno, J., Posada-de-la-Paz, M., Serrano-Aguilar, P.: Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res. (Hoboken) 66(3), 473–480 (2014)CrossRef

15.

Hudson, M., Thombs, B.D., Steele, R., Panopalis, P., Newton, E., Baron, M.: Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum. 61, 1112–1120 (2009)CrossRefPubMed

16.

Minier, T., Pentek, M., Brodszky, V., Ecseki, A., Karpati, K., Polgar, A., et al.: Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 49, 1920–1928 (2010)CrossRef

17.

Bernatsky, S., Hudson, M., Panopalis, P., Clarke, A.E., Pope, J., LeClercq, S., et al, and the Canadian Scleroderma Research Group: The cost of systemic sclerosis. Arthritis Rheum. 61, 119–123 (2009)

18.

Masserini, Belotti, Zeni, S., Cossutta, R., Soldi, A., Fantini, F.: Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients. Reumatismo 55, 245–255 (2003)

19.

Wilson, L.: Cost-of-illness of scleroderma: the case for rare diseases. Semin. Arthritis Rheum. 27, 73–84 (1997)CrossRefPubMed

20.

Strickland, G., Pauling, J., Cavill, C., McHugh, N.: Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools. Clin. Rheumatol. 31, 1215–1222 (2012)CrossRefPubMed

21.

Gualtierotti, R., Scalone, L., Ingegnoli, F., Cortesi, P., Lubatti, C., Zeni, S., et al.: Health related quality of life assessment in patients with systemic sclerosis. Reumatismo 62, 210–214 (2010)PubMed

22.

Hudson, M., Thombs, B.D., Steele, R., Panopalis, P., Newton, E., Baron, M.: The Canadian Scleroderma Research Group: quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions. J. Rheumatol. 36, 768–772 (2009)CrossRefPubMed

23.

Hudson, M., Steele, R., Taillefer, S., Baron, M.: The Canadian Scleroderma Research Group: quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis Rheum. 59, 270–278 (2008)CrossRefPubMed

24.

Andrade, T.L., Camelier, A.A., Rosa, F.W., Santos, M.P., Jezler, S., Pereira e Silva, J.L.: Applicability of the 12-Item Short-Form health survey in patients with progressive systemic sclerosis. J Bras Pneumol. 33, 414–422 (2007)CrossRefPubMed

25.

Khanna, D., Ahmed, M., Furst, D.E., Ginsburg, S.S., Park, G.S., Hornung, R., et al.: Health values of patients with systemic sclerosis. Arthritis Rheum. 57, 86–93 (2007)CrossRefPubMed

26.

Rannou, F., Poiraudeau, S., Berezne, A., Baubet, T., Le-Guern, V., Cabane, J., et al.: Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36- Item Short Form Health Survey. Arthritis Rheum. 57, 94–102 (2007)CrossRefPubMed

27.

Linertová, R., Serrano-Aguilar, P., Posada-de-la-Paz, M., Hens-Pérez, M., Kanavos, P., Taruscio, D., Schieppati, A., Stefanov, R., Péntek, M., Delgado, C., Graf von der Schulenburg, Persson, U., Chevreul, K., Fattore, G., Worbes-Cerezo, M., Sefton, M., López-Bastida, J., on behalf of BURQOL-RD Research Group: Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy 108(1), 19–26 (2012)CrossRefPubMed

28.

Lopez-Bastida, J., Monton-Alvarez, F., Serrano-Aguilar, P., Perestelo-Perez, L.: The social-economic costs in patients with ataxias cerebelosas in Spain. Mov. Disord. 23, 212–217 (2008)CrossRefPubMed

29.

Lopez-Bastida, J., Perestelo-Perez, L., Monton-Alvarez, F., Serrano-Aguilar, P., Alfonso-Sanchez, J.L.: Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 26, 1–7 (2008)

30.

Brooks, R.: EuroQol: the current state of play. Health Policy 37, 53–72 (1996)CrossRefPubMed

31.

Lopez-Bastida, J., Oliva, J., Perestelo-Perez, L., Serrano-Aguilar, P.: The economic costs and health-related quality of life of people with HIV and AIDS in the Canary Islands. Spain. BMC Health Serv Res. 9, 55–62 (2009)CrossRefPubMed

32.

McDaid, D.: Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int. J. Geriatr. Psychiatry 16, 400–405 (2001)CrossRefPubMed

33.

Van den Berg, B., Brouwer, W., Koopmanschap, M.: Economic valuation of informal care: an overview of methods and applications. Eur J Health Econ. 5, 36–45 (2004)CrossRefPubMed

34.

Hodgson, T.A., Meiners, M.R.: Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Mem Fund Q. 60, 429–491 (1982)CrossRef

35.

Drummond, M.F., O’Brien, B., Stoddart, G.L., Torrance, G.W.: Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford (1997)

36.

Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)CrossRefPubMed

37.

Mahoney, F.I., Barthel, D.W.: Functional evaluation: the Barthel Index. Md State Med 14, 61–65 (1965)

38.

Shah, S., Vanclay, F., Cooper, B.: Improving the sensitivity of the Barthel Index for stroke rehabilitation. J. Clin. Epidemiol. 42, 703–709 (1989)CrossRefPubMed

39.

Ruzafa, Cid: J., Damian Moreno, J.: Valoracion de la discapacidad fisica: el Indice de Barthel. Rev Esp Salud Publica. 71, 127–137 (1997)CrossRef

40.

Hérbert, R., Bravo, G., Préville, M.: Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging. 494–507 (2000)

41.

Szende, A., Janssen, B., Cabases, J. (eds.).: Self-Reported Population Health: An International Perspective based on EQ-5D. Springer, Netherlands (2014)

42.

Oliva, J., López-Bastida, J., Montejo, A.L., Osuna, R., Duque, B.: The socioeconomic costs of mental illness in Spain. Eur. J. Health Econ. 10, 361–369 (2009)CrossRef

43.

Angelis, A., Tordrup, D., Kanavos, P.: Socio-Economic Burden of Rare Diseases: A Systematic Review of Cost of Illness Evidence. Health Policy 119(7), 964–979 (2015)CrossRefPubMed

44.

Villaverde-Hueso, A., Sanchez-Valle, E., Alvarez, E., Morant, C., Carreira, P.E., Martin-Arribas, M.C., et al.: Estimating the burden of scleroderma disease in Spain. J. Rheumatol. 34, 2236–2242 (2007)PubMed

45.

Ghatnekar, O., Glenngard, A.H., Olofsson, S., Persson, U.: A literature review of instruments for measuring health-related quality of life in rare diseases: internal report of BURQOL-RD. The Swedish Institute for Health Economics. (2011)

46.

Furst, D., Khanna, D., Matucci-Cerinic, M., Clements, P., Steen, V., Pope, J., et al.: Systemic sclerosis: continuing progress in developing clinical measures of response. J. Rheumatol. 34, 1194–1200 (2007)PubMed

47.

Hu, T.W.: Perspectives: an international review of the national cost estimates of mental illness, 1990–2003. J. Ment. Health Policy Econ. 9, 3–13 (2006)PubMed

Titel: Social/economic costs and health-related quality of life in patients with scleroderma in Europe
verfasst von: Julio López-Bastida
Renata Linertová
Juan Oliva-Moreno
Pedro Serrano-Aguilar
Manuel Posada-de-la-Paz
Panos Kanavos
Domenica Taruscio
Arrigo Schieppati
Georgi Iskrov
Márta Péntek
Claudia Delgado
Johann Mathias von der Schulenburg
Ulf Persson
Karine Chevreul
Giovanni Fattore
The BURQOL-RD Research Network
Publikationsdatum: 02.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe Sonderheft 1/2016
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-016-0789-y

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2016

Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe

Social/economic costs and health-related quality of life in patients with rare diseases in Europe

Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe

Social/economic costs and health-related quality of life in patients with histiocytosis in Europe

Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe

Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe